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Abstract
In the early years of screening for prostate cancer with serum PSA, absolute cutoffs were
typically utilized such as greater than 4.0 ng/mL or even 2.5 ng/mL. A biopsy of the
prostate would commonly be recommended in a man with greater than 10-year life
expectancy who had a confirmed elevation above such a threshold or in the presence
of an abnormal digital rectal examination. The unmet need, however, is to be more
selective in recommending a prostate biopsy, due to the risk of complications and the
high rate of false-positive PSAs. More recently, various clinical nomograms can be used
to refine selection.  In addition,  clinicians can now utilize various advanced serum
biomarkers that have enhanced specificity—especially for the patient with a rising PSA
with prior negative biopsy. In this chapter, we will focus on the biomarkers PCA3,
Prostate Health Index, and 4 K score to illustrate key concepts in biomarker develop‐
ment and clinical utility.
Keywords: prostate cancer, prostate biopsy, PCA3, urine, Prostate Health Index, se‐
rum, 4 K score, serum
1. Introduction—a narrative on contemporary management of prostate
cancer risk with ordinary clinical tools
The male disease process “prostate cancer” is a heterogeneous entity at multiple subtop‐
ics including epidemiology, screening, diagnosis, treatment options, side effects, and cancer
control  results.  It  is  common  to  introduce  a  peer-reviewed  article  or  text  chapter  fo‐
cused on any aspect of prostate cancer with the observation that the disease is common
but  a  much smaller  subset  result  in  a  disease-specific  mortality—almost  to  the  point  of
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useless  repetition.  The heterogeneity  of  prostate  cancer  extends well  beyond population
statistics,  and in  this  chapter,  we  will  focus  on  one  aspect  of  heterogeneity—diagnosis.
The key paradigm in contemporary practice is  a male screened for prostate cancer with
serum prostate specific antigen (PSA) and digital rectal examination (DRE). The alternate/
related paradigm is the male with lower urinary tract or other pelvic symptoms who is
evaluated for  prostate  cancer with serum PSA/DRE as a  differential  diagnosis.  Perform‐
ing a biopsy and subsequent treatment has certainly altered key statistics in prostate cancer
compared  to  pure  clinical  detection.  The  incidence  has  increased  as  well  as  treatment
numbers.  Recently,  Welch  et  al.  demonstrated  with  SEER/Medicare  data  that  the  inci‐
dence  of  metastatic  disease  at  diagnosis  significantly  declined  with  the  introduction  of
PSA, compared with the relatively flat effect of mammography screening to breast cancer
staging [1].
The problem faced from this paradigm is that the results of a prostate biopsy are frustrating
for a growing list of reasons:
1. Too many negative or indeterminate biopsies.
2. Too many negative or indeterminate biopsies that are found to be falsely negative with
future evaluations.
3. Too many positive biopsies for low grade disease—leads to overtreatment.
4. Too many positive biopsies for low grade disease that with future radical prostatectomy
or repeat biopsies are found to have missed higher grade disease.
5. Cost, discomfort, and an occasional septic infection as the side effects of this effort to make
the correct diagnosis for a patient.
The concepts can be illustrated in the following case vignettes:
• A patient with Gleason Score 3+3 on biopsy has a radical prostatectomy, and the final
pathology showed Gleason 4+4.
• A patient with three negative biopsies has a continuous rising PSA—should he have a 4th
biopsy or accept the cause as benign?
• A patient with a negative biopsy and stable PSA—should he continue screening? What age
to stop?
• An elderly patient with Gleason 7 prostate cancer is unsure of overall longevity—does he
need curative therapy or just watchful waiting based on symptoms?
Physicians managing patients at risk for prostate cancer can certainly use clinical features to
frame many questions. In the asymptomatic patient who might have clinically localized
disease, a life expectancy of less than 10 years would be treated differently than a life expect‐
ancy greater than 10 years. Family history of prostate cancer (father, brothers, uncles) and
African American race are well-known adverse risk features for prostate cancer. The PSA has
its statistical problems with specificity (related to false positives), but does have sensitivity
(related to true positives) related to its value—higher PSAs have more risk of cancer, but hard
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to determine a clear line to draw where you call the test clearly normal versus abnormal.
Translating these narrated elements into summary numerical estimates (noncited as widely
available):
• For the common case with elevated PSA between 2.5 and 6.0, and leading to a prostate
biopsy, the overall cancer detection rate can be 30%, ±10% depending upon region. Of all
positive biopsies, 10–25% may have high grade elements. This means that the majority of
prostate biopsies are free of cancer, and an even higher number are free of clinically
significant cancer.
• For men with a previous negative biopsy, a repeat biopsy for continued rise is often positive
in 10–20%. Subsequent repeat biopsies lower the rate further but not to something ap‐
proaching zero.
• For men placed on active surveillance for low grade cancer, approximately 30% will be
upgraded at some point with repeat testing.
Moving forward, the unmet needs in prostate cancer evaluation are to increase the detection
of clinically significant disease when it is present, and to effectively rule out significant disease
when it is not present, such that subsequent monitoring can be reduced or eliminated. To
emphasize—both of these needs are critical and equal: the need to diagnose cancer that is present and
potentially lethal, and the need to eliminate diagnostic attempts when cancer is absent or nonlethal.
2. Prostate biopsy triggers—mild improvement from mathematics and
clinical trials
In a state-of-the-art lecture at the 2015 American Urological Association Annual Meeting, Stacy
Loeb (New York, USA) made the key analogy that the first 10 or more years of use of PSA was
analogous to a pregnancy test—in search of when to call the test positive or negative. The initial
cut-point was 4.0, and many labs still flag a result in red at >4.0, and subsequent proposals
were for >2.5. Clinical experience clearly showed the fallacy of this version of laboratory
medicine—a man’s risk of prostate cancer does not go from zero at PSA 3.9 to 100% at PSA of
4.1. The point was well illustrated by a follow-up report from the Prostate Cancer Prevention
Trial that showed the biopsy results of men with different PSA cut-points who were all biopsied
and on a placebo medication—sample size of 2950 participants and 449 cancers [2].Table 1
shows a sample of their report. Note that the pregnancy illustration was carried forward in
this trial, as men with a PSA > 4.0 were biopsied “for cause” and the data represent the men
followed for the 7-year duration of the trial who were considered clinically “normal range”.
Prior to this publication, there was very limited data available on the results of a prostate biopsy
in men with a normal DRE and PSA < 4.0.
With this data, you can certainly counsel a man on the concept of a relative range of prostate
cancer risk rather than oversimplify it to a positive/negative result. This same dataset was
refined further into an online calculator tool where you can input multiple clinical variables
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and receive an estimate on overall cancer detection and high grade (Gleason 7 or higher) cancer.
The web link is: http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp.
Here are two example cases:
1. Race Caucasian, age 59, PSA 2.1, no family history, abnormal DRE, no prior biopsy. Result:
3% high-grade cancer, 14%, low-grade cancer, and 83% negative biopsy.
2. Race African American, age 59, PSA 9.8, positive family history for prostate cancer, DRE
abnormal, no prior biopsy. Result: 35% high-grade cancer, 20% low-grade cancer, 45%
negative biopsy.
PSA level Percentage positive biopsy Percentage of positive biopsies with high grade
≤0.5 6.6 12.5
0.6–1.0 10.1 10.0
1.1–2.0 17.0 11.8
2.1–3.0 23.9 19.1
3.1–4.0 26.9 25.0
Table 1. Data from the Prostate Cancer Prevention Trial [2]. This cohort of men were biopsied as part of the trial design
and were on a placebo. Men with a PSA > 4.0 would have been biopsied earlier “for cause”.
The results also remind you that regardless of the biopsy result, there may be a 2–4% chance
of an infection requiring hospitalization. Thus, the absolute risks of cancer and side effects can
be discussed and a personalized choice made. We should not forget why we are considering
these efforts. The third update to the Bill-Axelson trial of radical prostatectomy versus watchful
waiting reminds us that the treatment arm had a 12.7% absolute difference in overall mortality,
with a relative risk of 0.71 in favor of surgery and number needed to treat to avoid a death of
1:8 [3]. Additional benefits were observed in palliation, metastatic progression, and androgen
deprivation utilization.
3. Biomarkers in prostate cancer—highlights of evaluation and early
improvement of specificity
As established thus far, PSA is the gold standard for prostate cancer detection. Many experts
have voiced the opinion that this might change in the next generation [4]. First, we should
review key biomarker nomenclature recognized by the FDA—whether a biomarker is serum,
urine, or tissue base. Table 2 shows four key distinctions and a biomarker such as PSA has
elements of all four.
Data on biomarkers is a separate and vast topic and we will not review it. But the key headings
would be whether a study is in preclinical exploratory trials, assay development, assay
validation, retrospective use/repositories, prospective screening, or randomized controlled.
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Biomarkers can be described based on their validity with a number of statistical expression
and eventually need to be described based upon clinical utility, i.e., strength of ability to alter
key clinical decisions and add value to health care.
Biomarker type When Indications
Prognostic Prior to treatment Risk of a specific outcome
Predictive Prior to treatment Identify which patients benefit from a treatment
Response indicator During or after treatment Response to treatment (pharmacology, physiology)
Efficacy-response (surrogate) After treatment Early/accurate prediction of a clinical endpoint
Table 2. FDA biomarker classification based on context of use.
As stated, there are many statistical advantages to PSA screening compared to using prostatic
acid phosphatase (PAP) [5], or clinical exam [6]. However, there is significant room to improve
accuracy and especially specificity. Early efforts to make progress were numerous such as
adding the percent-free PSA to PSA ratio [7], age adjustment [8], PSA velocity of ≥0.75 ng/mL/
year [9], and PSA density of 0.15 [10]. These methods all made incremental practice, but
perhaps the most significant is in making decisions about a repeat biopsy versus a primary
biopsy. Another useful contribution to PSA screening interval questions came from Lilja et al.,
who showed that a single PSA before age 50 could be predictive of lifetime prostate cancer
incidence [11].
4. A focus on novel diagnostic biomarkers: prostate Health Index and 4 K
score
Similar themes in advancing future prostate cancer screening have come from focusing on
“isomers” or molecular variants of the PSA molecule. Another variant of PSA is called Pro-
PSA and can be more prevalent in the free-fraction within cancer versus noncancer [12]. In a
validation study of Pro-PSA versus percent-free PSA, the area under the curve (AUC) was 0.68
for %ProPSA and 0.567 for %free PSA. At sensitivity of 75%, the %ProPSA would eliminate
59% of negative biopsies versus 33% with %fPSA [13]. Catalona et al. [14] also did a serum
bank study on biopsied patients with elevated PSA and found the %proPSA can eliminate 19–
33% of biopsies while holding 90% sensitivity.
The next iteration came from the discovery of an isoform p2PSA, and the concept of combining
the information with free PSA and total PSA into an equation: ([−2]pPSA/fPSA)/√(tPSA). This
is now the Prostate Health Index and licensed by Beckman Coulter laboratories. Jansen et al.
[15] reported a multisite study showing that prostate cancer patients had higher PHI levels
and %p2PSA. A U.S. validation study of 829 patients holding sensitivity at 95% had specificity
of 16% for PHI and 8.5% for %fPSA [16]. Relevant to our case vignettes in the introductory
narrative, the higher PHI values were also correlating with a higher risk of Gleason score ≥7.
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A PHI score is currently reported in four “brackets” of results: 0–24.9, 25.0–34.9, 35.0–54.9, and
>55. The PHI, as stated will include a total PSA, the free PSA, and the Pro-PSA. The PHI result
is then translated into a percentage risk of prostate cancer. The source reference [16] includes
the high grade numbers, but an actual test result for some reason does not. Table 3 shows a
commercial report range. The study listed ranges for Gleason ≥7 were PHI 0–24.9 = 26.1%, PHI
25.0–34.9 of 28.2%, PHI 35.0–54.9 of 30.1%, and PHI >55.0 of 42.1%. Thus, the trends are
strongest comparing the lowest versus highest PHI brackets.
Biomarker Sample result Reference interval
Total PSA 7.8 Normal < 2.0
At risk ≥ 2.0
Free PSA 1.16 See below
Pro2PSA 20.78 See PHI
%free PSA 15 % Free PSA prostate cancer probability by age
%Free PSA <60 60–70 >70
<7 85% 95% 96%
7–15 25% 50% 60%
16–25 11% 27% 35%
>25 2% 6% 10%
PHI 49.9 PHI Cancer probability
0–24.9 11.0%
25.0–34.9 18.1%
35.0–54.9 32.7%
>55.0 52.1%
Table 3. PHI result reporting as of 2015.
A European cohort was published by Lazzeri et al. [17] and showed an AUC of 0.67 for PHI
as well as %proPSA—both superior to total PSA and %free PSA. At a PHI cutoff of 27.6, biopsies
could have been avoided in 15.5%. The Gleason ≥7 trend was also observed in their statistical
analyses.
Another research direction developing in parallel has been human glandular kallikrein 2—
hK2. It is also part of the serine protease family along with PSA. Nam et al. [18], for example,
looked at hK2 and hK2 to %free PSA ratios could find trends elevated in PCa. Vickers et al.
then expanded the concept as a panel of Kallikrein markers: total PSA, free PSA, intact PSA,
and hK2. This coined the phrase 4 K score [19]. The process developed a nomogram that
includes the four markers, age, DRE, and determines a probability of cancer. The model adds
to a clinical base model and increases prediction for high grade prostate cancer. The AUC for
the full model was 0.832 and high-grade cancer was 0.870, and a decision curve analysis is
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presented to propose a threshold value of 20% as a biopsy trigger that would spare a significant
number of biopsies and only miss 3% high-grade cancers. Parekh et al. [20] then published a
U.S. prospective trial that used the PCPT risk calculator above as a control. Again, the full
model had an AUC of 0.821 and higher AUC for Gleason ≥7, as well as decision curve benefit.
As an illustration, a 4 K score cutoff of 9% led to 43% of biopsies avoided and 2.4% risk of delay
in Gleason ≥7 diagnosis.
For the clinician, the question then becomes which test to use? PHI had a slight advantage in
being earlier in regulatory approval. Nordstrom et al. presented a comparison study of PHI
versus 4 K [21]. The PHI and 4 K both had improved prediction for overall and high grade
prostate cancer. The AUC for 4 K was 0.69 and for PHI was 0.704, and for high-grade prostate
cancer was 0.718 and 0.711, respectively. Comparable metrics were observed with a 4 K cutoff
of 10% and PHI of 39.
PHI 4K PCA3
Components Serum ([−2]pPSA/fPSA)/√(tPSA) Serum tPSA, fPSA, intact PSA,
hk2, age Clinical model (add DRE
results)
Urine; (mRNA PCA3/
mRNA PSA) × 1000
Patient
population
>50 y/o, PSA 4–10 ng/mL, normal
DRE
Any patient referred for TRUS Bx >50 y/o; prior negative Bx
FDA
approval
2012 n/a 2012
Outcome
measure
PCa High risk PCa (GS ≥ 7) PCa
Cutoff 0–29 = low risk; 8.7% risk PCa
21–39.9 = mod risk; 20.6% risk
PCa >40 = high risk; 43.8% risk
PCa
≥9%, eliminates 43% of
unnecessary Bx, w/2.4% risk of
delayed dx of
HG PCa
>35 sensitivity = 58%, and
specificity = 72% for PCa
Disadvantages Not currently covered by
private insurances/Medicaid/
Medicare
Requires prostate message
Comparisons Comparable diagnostic accuracy
to both 4 K and PCA3, and both
their recommended indications
No comparison to PCA3;
comparable accuracy and
utility to 4 K
No comparison to 4 K;
comparable diagnostic
accuracy to PCA3 for initial
& repeat Bx
Cost $71–80 $395 $385
Table 4. Comparison of serum biomarkers PHI, 4K, and urine biomarker PCA3.
Another biomarker with a little more clinical experience and validation data is the PCA3 score
—different in being a urinary marker rather than serum as for PHI and 4 K. The assay uses a
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ratio of messenger RNA for the PCA3 molecule with a PSA ratio built in. The AUCs for PCA3
are generally in the 0.0.68–75 range [22]. In the validation study for repeat biopsy patients,
Marks et al. showed an AUC of 0.68 for PCA3 versus 0.52 for PSA [23]. The cutoffs recom‐
mended are in the 25–35 range. In the Marks study, a PCA3 cutoff of 35 showed 58% sensitivity
and 72% specificity. A particular advantage of PCA3 has been that it is not affected by prostate
volume and performed well across multiple PSA levels [24].
Back to comparative studies, Ferro et al. compared PCA3 to PHI in a prospective observational
study [25]. The diagnostic accuracy was similar at 90% sensitivity: PHI specificity of 40% and
PCA3 of 40% with 31.6 and 22 cutoffs, respectively. In a decision curve analysis, PHI had
slightly higher benefit at probability of 25%. The Scattoni study [26] looked at these markers
in initial and repeat biopsy populations and found a slight benefit to PHI but not significant.
A comparison of AUC for initial biopsy showed PSA of 0.54, %fPSA of 0.67, PCA3 of 0.57, and
PHI of 0.69. In repeat biopsy, it showed PSA of 0.60, %fPSA of 0.52, PCA3 of 0.63, and PHI of
0.72.
In Table 4, we consolidate these statistics into a final comparison with existing data.
The cost comparison certainly favors PHI, although the PCA3 test has more clinical experience
and strong metrics in repeat biopsy decisions. It remains to be determined whether the 4 K
cost is justified; however, when this test is up and running and through regulation, it may give
a more objective reporting of specific high grade prostate cancer risk that clinicians may prefer.
5. Moving forward—similar themes in imaging, biopsy techniques, and
tissue biomarkers
In this chapter, we have outlined the PSA problem with emphasis on triggers for a biopsy. A
separate but related topic is the technique of biopsy. The gold standard for all of these
biomarker studies has been the 10–12 core transrectal ultrasound-guided biopsy. Emerging
data, however, demonstrate that a transperineal template biopsy may sample the apex and
anterior zones better. Other areas of research are looking at improvements in multiparametric
MRI staging, and commercial software platforms that fuse the images such that an ultrasound
biopsy now has a more accurate target to sample rather than random sampling by anatomic
region. The endpoints are the same—ability to improve Gleason score ≥7 and the ability to
trust that a negative test is actually negative. For diagnosed patients, commercial genetic
profiling products can then look at specific grades of prostate cancer and offer additional
prognostic information such as risk of upgrading/upstaging at surgery, mortality rates
untreated, biochemical relapse after surgery, or metastatic relapse after surgery [27]. These
topics can be separate chapters, but the themes are consistent—solving heterogeneity in
prostate cancer diagnosis such that the downstream monitoring and treatment decisions are
optimized.
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